InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar naughtyguy (30.66) Submitted: 2/24/2013 7:25:05 AM : Outperform Start Price: $8.93 ITMN Score: +56.12

might be worth more than 1/2billion market cap??

Featured Broker Partners


Advertisement